Physician profile
Mark B Mcintee
NPI 1851529978
$4,826.15
in general payments reported to CMS, 2019-2025
30 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,618 · 2023: $907 · 2024: $909 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,932 · Consulting Fee: $200 · Education: $75.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,931.95 |
| Consulting Fee | $200.00 |
| Education | $75.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,578.52 | 2022-2023 | |
| Nevro Corp. | $1,104.74 | 2023-2024 | Senza |
| Globus Medical, INC. | $381.87 | 2025 | Senza, Omnia |
| Avadel Cns Pharmaceuticals, LLC | $297.99 | 2024-2025 | Lumryz |
| Pfizer INC. | $199.22 | 2023-2025 | |
| Tg Therapeutics, INC. | $159.54 | 2023-2025 | |
| Abbvie INC. | $152.62 | 2024-2025 | |
| Mml US, INC. | $134.80 | 2022 | |
| Ucb, INC. | $119.41 | 2025 | Fintepla, Briviact |
| Abbott Laboratories | $101.36 | 2024 | Eterna |
| Teva Pharmaceuticals USA, INC. | $75.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.08 | 2025 | Hyqvia |
| Ani Pharmaceuticals, INC. | $50.42 | 2025 | Purified Cortrophin Gel |
| Neurocrine Biosciences, INC. | $47.32 | 2024-2025 | Ingrezza |
| Alnylam Pharmaceuticals INC. | $42.32 | 2025 | Givlaari |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $36.49 | 2025 | Ponvory |
| Celgene Corporation | $33.64 | 2022-2025 | Zeposia |
| Csl Behring | $31.16 | 2025 | Hizentra |
| Emd Serono, INC. | $22.45 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.11 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $21.35 | 2025 | Symbravo |
| Biohaven Pharmaceutical Holding Company LTD. | $20.40 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.54 | 2024 | |
| Collegium Pharmaceutical, INC. | $18.93 | 2024 | Xtampza |
| Biogen, INC. | $18.52 | 2025 | Skyclarys |
| Otsuka America Pharmaceutical, INC. | $18.02 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $17.90 | 2025 | Daybue |
| Neurelis, INC. | $13.91 | 2023 | Valtoco |
| Alexion Pharmaceuticals, INC. | $13.75 | 2025 | Ultomiris |
| Lilly USA, LLC | $12.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mcintee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.